BCL2 and neoplasm: RNA interference (RNAi) therapy has emerged as a powerfultoolin this context, offering the ability to selectively silence genesinvolved in drug resistance and tumor progression, such as survivinand BCL-2. By disrupting these key resistancepathways, RNAi can improve the selectivity and potency of chemotherapy.However, to fully realize the potential of RNAi-based therapies, wemust also develop effective delivery systems capable of transportingnucleic acid cargo into tumor cells, particularly in aggressive, treatment-resistantcancers like TNBC.